



# LKT Laboratories, Inc.

## Terazosin Hydrochloride Dihydrate

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

### Product Information

**Product ID** T1670

**CAS No.** 70024-40-7

**Chemical Name** 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine monohydrochloride dihydrate

**Synonym** Heitrin, Hytracin, Hytrin, Hytrinex, Itrin, Urodie, Vasocard

**Formula** C<sub>19</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub> · HCl · 2H<sub>2</sub>O

**Formula Wt.** 459.93

**Melting Point** 271-274 °C


**Purity** ≥98%

**Solubility** Soluble in water (<1 mg/mL), DMSO (25 mg/mL), ethanol (<1 mg/mL), methanol, chloroform.

**Store Temp** Ambient

**Ship Temp** Ambient

**Description** Terazosin is a quinazoline compound that inhibits α<sub>1</sub>-adrenergic receptors, exhibiting antihypertensive, anti-metastatic, and anticancer activities. Terazosin is clinically used to treat benign prostatic hyperplasia (BPH) and hypertension. In prostate cells, terazosin increases activation of caspase 3 and induces apoptosis. In prostate cancer cells, this compound induces apoptosis and inhibits cellular proliferation, invasion, and migration.



**Bulk quantities available upon request**

Product ID	Size
T1670	50 mg
T1670	250 mg
T1670	1 g

**References** Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α<sub>1</sub>-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. *Expert Opin Drug Saf.* 2014 Sep;13(9):1187-97. PMID: 25073735.

Papadopoulos G, Vlachodimitropoulos D, Kyroudi A, et al. Terazosin treatment induces caspase-3 expression in the rat ventral prostate. *J Clin Med Res.* 2013 Apr;5(2):127-31. PMID: 23518907.

Tahmatzopoulos A, Rowland RG, Kyprianou N. The role of alpha-blockers in the management of prostate cancer. *Expert Opin Pharmacother.* 2004 Jun;5(6):1279-85. PMID: 15163273.

Tomoda F, Takata M, Yoshida K, et al. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment. *Am J Hypertens.* 1989 Nov;2(11 Pt 1):834-9. PMID: 2574044.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.